At Anumana, our mission is to use the power of AI to unlock the electrical language of the heart.

Right now, millions of Americans have conditions that put them at risk of developing heart failure (HF), even if they are not experiencing HF symptoms. These HF risk factors include hypertension, atherosclerosis, diabetes, family history, and other conditions that increase the risk of HF. Their hearts may be struggling, but the signs are subtle, easily missed, or attributed to aging or being out of shape. By the time symptoms become obvious, the disease has often progressed significantly.^4,5

Common methods of detecting HF can have limits. Standard 12- lead ECGs can look completely normal even when heart function is compromised. Echocardiograms can be expensive and time-consuming, and may not be covered if symptoms are not present. The result? Too many people discover their heart condition far later than they should.

The information might have been there, hidden in the electrical signals of every heartbeat. We just couldn’t see it. Until now.

At Anumana, we’ve taught AI to read the language that hearts have been speaking all along. Our FDA-cleared ECG-AI™ LEF technology analyzes a standard 10-second ECG and detects patterns invisible to the human eye, patterns that reveal reduced heart function before traditional methods can catch it.

This isn’t theoretical. It’s not a research project. Our technology is used in clinical practice today, providing patients and their physicians crucial information from a test that takes seconds and can cost a fraction of other diagnostic approaches.

We’re turning the most common cardiac test – one that happens thousands of times a day³ into a powerful early detection tool for heart failure. Same ECG. Completely different insights.

Our ECG-AI™ LEF technology is built on rigorous science and real-world validation:

• The ECG-AI™ Platform was modeled on nearly 2.9 million ECG-echo pairs and 676K+ patients across diverse populations.¹
• Latest clinical performance demonstrates 90.2% sensitivity and 85.1% specificity in detecting low ejection fraction, exceptional performance in diagnostic testing.¹
• Over 30 peer-reviewed publications demonstrate the clinical validity and utility of our approach. We’re not making promises, we’re sharing proven results.¹
• FDA clearance means our ECG-AI LEF has met the standards for safety and effectiveness. This is technology that clinicians can trust and use in patient care.²
• Commercial deployment across healthcare systems means providers are using Anumana today. We have established CPT codes and reimbursement pathways. This is real technology solving real problems right now.¹
• Ongoing clinical research continues to expand our understanding of how ECG-AI can transform cardiac care, with new findings being presented at major cardiology conferences worldwide.

Anumana was founded by nference and Mayo Clinic, bringing together cutting-edge AI capabilities with world-renowned cardiovascular expertise. Our name itself reflects this approach: Anumana (pronounced Ah-noo-maa-naa) is Sanskrit for “inference,” one of the five means of knowledge in Indian philosophy, meaning to use observation, previous truths, and reason to reach a new conclusion.

That philosophy guides everything we do. We combine massive clinical datasets, deep cardiovascular knowledge, and sophisticated AI to see what others can’t. We’re not guessing. We’re not extrapolating. We’re uncovering truths that have been there all along, waiting to be revealed.

From our founding, we’ve been built on a commitment to scientific rigor, clinical validation, and real-world impact. We don’t just publish papers, we change how care is delivered.